Astria Therapeutics
ATXS
ATXS was delisted on the 22nd of January, 2026.
102 hedge funds and large institutions have $811M invested in Astria Therapeutics in 2024 Q1 according to their latest regulatory filings, with 34 funds opening new positions, 38 increasing their positions, 25 reducing their positions, and 12 closing their positions.
485% more call options, than puts
Call options by funds: $51M | Put options by funds: $8.72M
184% more capital invested
Capital invested by funds: $286M → $811M (+$525M)
183% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 12
52% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 25
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
28% more funds holding
Funds holding: 80 → 102 (+22)
2.41% more ownership
Funds ownership: 102.58% → 104.98% (+2.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
TCG Crossover Management
Palo Alto,
California
|
+$65.7M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$55M |
| 3 |
PA
Perceptive Advisors
New York
|
+$30.9M |
| 4 |
State Street
Boston,
Massachusetts
|
+$21M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$19.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$12.9M |
| 2 |
AC
Armistice Capital
New York
|
-$12.1M |
| 3 |
RA
Rosalind Advisors
Toronto,
Ontario, Canada
|
-$8.67M |
| 4 |
SC
Stempoint Capital
New York
|
-$7.8M |
| 5 |
AAA
Affinity Asset Advisors
New York
|
-$7.73M |
ATXS Hedge Fund Activity: Q1 2024 in Review
102 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Astria Therapeutics (ATXS) for Q1 2024, worth a combined $811M — up 184% from $286M a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new ATXS positions and 12 closed out — a net gain of 22 holders — while 38 added to existing stakes and 25 trimmed.
The largest buyer was TCG Crossover Management, opening a new position worth an estimated $65.7M. The largest seller was Sphera Funds Management, cutting an estimated $12.9M.
- 102 institutional investors held Astria Therapeutics (ATXS) as of Q1 2024, up from 80 in Q4 2023.
- Funds reported $811M of Astria Therapeutics stock for Q1 2024, up 184% quarter-over-quarter.
- 34 funds opened new Astria Therapeutics positions in Q1 2024 and 12 closed out, a net change of +22 holders.
- The largest Astria Therapeutics buyer in Q1 2024 was TCG Crossover Management, an estimated $65.7M added.
- The largest Astria Therapeutics seller in Q1 2024 was Sphera Funds Management, an estimated $12.9M sold.
Based on aggregated 13F filings for Q1 2024.